Breaking Down Zhejiang Hisun Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Zhejiang Hisun Pharmaceutical's recent numbers demand a close look: Q1 2025 revenue was CNY 2.63 billion (down from CNY 2.73 billion in Q1 2024) while TTM revenue as of Sept 30, 2025 reached CNY 9.84 billion (a 3.02% increase year-over-year), following full-year 2024 revenue of CNY 9.79 billion (a 5.65% decline versus 2023); profitability showed a sharp turnaround with 2024 net income of CNY 601.2 million (from a CNY 93.2 million loss in 2023) and a 43.8% gross margin, but liquidity and leverage paint a mixed picture-net debt fell to CNY 2.56 billion (from CNY 5.35 billion a year earlier), debt-to-equity is 0.39, current ratio 0.95 and quick ratio 0.61-while valuation sits at a TTM P/E of 20.09 and market cap of CNY 12.79 billion; regulatory headwinds (FDA warning letters and a Sept 2024 ban on most APIs from the Taizhou facility into the U.S.), slower projected revenue growth (~1.9% annually vs. ~10% sector growth), and heavy API reliance contrast with upside levers such as a CNY 100 million buyback, a planned cash dividend of CNY 2.10 per 10 shares, expansion into 70+ countries and investments in biopharma innovation-read on for a data-driven breakdown of what these metrics mean for investors.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) - Revenue Analysis

• Q1 2025 revenue: CNY 2.63 billion (Q1 2024: CNY 2.73 billion)
• TTM revenue (as of 2025-09-30): CNY 9.84 billion (+3.02% YoY)
• FY 2024 revenue: CNY 9.79 billion (-5.65% vs. 2023)
• Revenue per employee: ~CNY 1.23 million (workforce: 7,994)
• Price-to-Sales (P/S): 1.30
• Market capitalization: CNY 12.79 billion

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) - Profitability Metrics

• Net income (2024): CNY 601.2 million (vs. net loss CNY 93.2 million in 2023)
• Profit margin (2024): 6.1% (from negative in 2023)
• Operating margin: 12.16%
• Gross profit margin (2024): 43.8% (up from 39.2% in 2023)
• Return on assets (ROA): 2.79%
• Return on equity (ROE): 6.35%
• EPS (TTM): CNY 0.53

• Drivers: improved gross margin (+4.6 percentage points YoY) suggests better pricing, product mix or lower COGS; operating margin at 12.16% signals controlled operating expenses.
• Investor focus: monitor sustainability of gross margin gains and conversion of operating margin into net income given prior-year loss.
• Valuation input: EPS CNY 0.53 and positive ROE support continued earnings-based valuation models; compare market price for P/E context.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) - Debt vs. Equity Structure

• Net debt reduced to CNY 2.56 billion (Mar 2025) from CNY 5.35 billion (Mar 2024) - a decline of CNY 2.79 billion year-over-year.
• Debt-to-equity ratio: 0.39, consistent with a conservative capital structure.
• Debt-to-EBITDA ratio: 1.74, indicating debt levels that are moderate relative to operating earnings.
• Interest coverage ratio: 7.71, demonstrating comfortable ability to service interest expense from operating profit.
• Net debt to equity: 29.1%, reflecting modest financial leverage after accounting for cash and equivalents.
• Current ratio: 0.95, slightly below the 1.0 benchmark and signaling potential short-term liquidity pressure.

• Reduced net debt improves flexibility for capex, R&D, and potential M&A while lowering refinancing risk.
• Healthy interest coverage (7.71) and low debt-to-EBITDA (1.74) suggest resilience of operating cash flows against debt service.
• Net debt/equity at 29.1% supports a balance between using leverage for growth and preserving balance-sheet strength.
• Current ratio of 0.95 warrants monitoring of short-term liquidity management (receivables, inventories, payables and short-term borrowings).

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) - Liquidity and Solvency

• Current ratio: 0.95 - slightly below the 1.0 benchmark, signaling potential near-term liquidity pressure if receivables or inventories cannot be converted quickly to cash.
• Quick ratio: 0.61 - indicates limited ability to meet short-term liabilities without relying on inventory sales.
• Interest coverage ratio: 7.71 - a comfortable buffer showing operating earnings cover interest expense multiple times over, reducing default risk on interest payments.
• Debt-to-EBITDA: 1.74 - suggests debt levels are manageable relative to operating earnings, implying room to service and reduce leverage.
• Net debt / equity: 29.1% - a moderate leverage ratio consistent with conservative capital structure.
• Return on assets (ROA): 2.79% - indicates the company generates modest returns from its asset base, reflecting asset utilization efficiency in context of the sector.

• Near-term liquidity: monitor working capital trends (receivables, payables, inventory turnover) given current ratio <1 and quick ratio well below 1.
• Solvency and debt service: strong interest coverage (7.71) and low debt-to-EBITDA (1.74) reduce refinancing and default risk in the medium term.
• Leverage profile: net debt/equity at 29.1% supports a conservative balance-sheet stance while allowing room for strategic investments or M&A.
• Profitability vs. assets: ROA of 2.79% suggests modest returns - watch margin trends and asset turnover for improvement potential.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) - Valuation Analysis

• Trailing twelve months (TTM) P/E: 20.09 - a moderate valuation relative to recent earnings.
• Forward P/E: 28.78 - implies the market is pricing in expected earnings growth or higher near-term uncertainty.
• Price-to-Book (P/B): 1.46 - investors are paying about 1.46x the company's net asset book value.
• Enterprise Value / Revenue (EV/R): 1.41 - indicates the firm's valuation is roughly 1.4 times annual revenue.
• EV/EBITDA: 7.50 - a mid-range multiple suggesting reasonable operating earnings valuation.
• EV/FCF: 7.43 - the market values free cash flow at about 7.4 times, signaling attractive cash-flow valuation versus many peers.
• Market Capitalization: CNY 12.79 billion - reflects aggregate investor valuation of equity.

• Relative perspective: a forward P/E notably higher than the TTM P/E points to either anticipated margin/earnings expansion or conservatism in near-term analyst estimates; reconcile by reviewing guidance, pipeline milestones, and one-off items in trailing earnings.
• Enterprise-value multiples (EV/R, EV/EBITDA, EV/FCF) all clustering in the 1.4-7.5 range imply the market places value both on top-line scale and on cash generation - useful when comparing against domestic pharma peers or sub-sector medians.
• P/B near 1.5 suggests limited balance-sheet discount; investors focusing on capital-light growth or intangible-driven upside should weigh this against R&D pipeline valuation and intangible asset treatment.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) - Risk Factors

• Regulatory risk: FDA warning letters and a U.S. import ban. In September 2024 the U.S. banned most APIs from Hisun's Taizhou facility from entering the U.S. market following inspection findings and warning letters. This restricts access to a high‑value export market and creates remediation costs, potential product recalls, and lost sales.
• Business concentration: Heavy reliance on the API segment exposes the company to margin volatility, demand shocks and single‑site operational disruptions (Taizhou), amplifying supply‑chain and client‑concentration risk.
• Growth gap vs. sector: Management's projected revenue growth of ~1.9% p.a. for the next two years compares unfavorably to the broader Chinese pharmaceutical sector's expected ~10% annual growth, implying risk of market share erosion and downward pressure on pricing power.
• Liquidity constraints: A current ratio of 0.95 and quick ratio of 0.61 indicate limited short‑term cushion to meet liabilities without relying on inventory liquidation or fresh financing.
• Leverage profile: Debt‑to‑equity of 0.39 shows conservative use of debt, lowering solvency risk but potentially limiting flexibility to finance remediation, capacity expansion or M&A without diluting equity or paying higher borrowing costs.
• Operational remediation costs: Compliance actions (facility upgrades, quality system overhauls, third‑party audits) will require CAPEX and OPEX that strain free cash flow, especially if U.S. revenue remains restricted.

• Investor considerations: remediation timeline and successful lifting of the Taizhou ban are binary catalysts; ongoing margin pressure from API pricing or lost U.S. volume could materially reduce EBITDA margins and free cash flow.
• Financial flexibility: with current liquidity ratios below 1.0 and modest leverage headroom, the company may need to access equity or higher‑cost debt to fund compliance CAPEX, which would affect shareholder returns.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) - Growth Opportunities

Zhejiang Hisun Pharmaceutical is positioning itself for sustained growth through R&D in biopharmaceuticals, international expansion, shareholder-friendly capital actions, and improving profitability metrics. Key quantitative indicators and strategic moves below highlight areas where the company can capture additional market share and enhance long-term investor value.

• Biopharmaceutical innovation: increased R&D focus and pipeline development targeting higher-margin biologics and specialty medicines.
• Global footprint expansion: marketed products present in over 70 countries, supporting revenue diversification and foreign market upside.
• Capital allocation signaling confidence: CNY 100 million equity buyback announced in May 2025 to support share price and EPS.
• Shareholder returns: proposed cash dividend of CNY 2.10 per 10 shares for 2024 to enhance investor yield.
• Operational efficiency: gross profit margin expanded to 43.8% in 2024, reflecting improved cost management and pricing power.
• Return metrics: ROE at 6.35% indicating effective equity utilization with room to improve as margins and leverage optimize.

Strategic priorities that underlie these metrics and offer growth levers include:

• Advancing biopharma R&D to move up the value chain from small-molecule generics to higher-margin biologics and specialty drugs.
• Expanding commercial channels and regulatory approvals in additional international markets to leverage the existing 70+ country footprint.
• Using the buyback and dividend policy to support equity valuations while balancing cash for R&D and M&A opportunities.
• Continuing margin improvement initiatives-manufacturing efficiencies, procurement optimization, and portfolio mix shift toward higher-margin products.

For context on corporate background, ownership and strategic evolution see: Zhejiang Hisun Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money